Case no | References | Year | Gender | Age | Catheter removal | Antimicrobials | Route of Administration | Outcome |
1 | (8) | 1984 | Female | 74 | No | Trimethoprim Sulfamethoxazole Ampicillin | IP | Cured |
2 | (8) | 1984 | Male | 33 | Yes | 1) Cefazolin IP + tobramycin IP (duration NR) 2) Ampicillin IP for 5 days 3) Amoxicillin orally for 7 days 4) After catheter removal, tobramycin IV (duration NR) | IP, IV | Catheter removed on day 12 after the start of antibiotic therapy |
3 | (9) | 1985 | Male | 61 | No | Vancomycin IP + gentamicin IP (duration NR) | IP | Cured |
4 | (10) | 1985 | Male | 50 | No | 1) Cephalothin IP for 4 days 2) Tobramycin IP for 14 days | IP | Cured |
5 | (10) | 1987 | Female | 65 | Yes | 1) Vancomycin for 10 days + tobramycin 12 days + ampicillin for 3 days (route NR) 2) Mezlocillin for 13 days + cefoxitin for 13 days (route NR) 3) Chloramphenicol for 13 days (route NR) | IP | Catheter removed (day NR) |
6 | (11) | 1988 | Female | 38 | Yes | Tobramycin Ciprofloxacin | IP | Catheter removed on 7 day |
7 | (12) | 1990 | Male | 64 | No | 1) Ciprofloxacin orally for 3 days 2) Netilmicin IP (duration NR) | OS, IP | Cured |
8 | (13) | 2008 | Male | 50 | Yes | 1) Vancomycin IP, single dose 2) Imipenem IV + gentamicin IP for 18 days 3) After catheter removal, imipenem IV for 7 days | IP, IV | Catheter removed on day 21 after the start of antibiotic therapy |
9 | (14) | 2011 | Female | 3.5 | No | 1) Amikacin IP for 4 days 2) Meropenem IV for 7 days | IP, IV | Cured |
10 | (15) | 2013 | Male | 63 | Yes | Cefazolin IP (1 g/day) + Ceftazidime IP (1 g/day) 1st relapse: Imipenem IP (1 g) | IP | Catheter Removed Hemodialysis |
11 | (16) | 2015 | Female | 50 | No | 1) Tobramycin for 21 days 2) Meropenem IV for 21 days | IV | Cured |
12 | (17) | 2016 | Female | 50 | Yes | Ceftazidime | IP | Cured |
13 | (18) | 2018 | Female | 63 | No | Ceftazidime Amikacin | IP | Cured |
14 | (19) | 2019 | Male | 35 | Yes | intraperitoneal (IP) ampicillin/sulbactam and ceftazidime | IP | Catheter Removed Hemodialysis |
15 | Our study | 2019 | Male | 52 | No | Ciprofloxacin Meropenem | IP | Cured |